Real World Virologic Outcomes in Patients With Elevated Body Mass Index Receiving Long Acting Cabotegravir/Rilpivirine
The data from this real-world cohort demonstrates no difference in virologic outcomes for individuals with BMI ≥30 kg/m2 as compared to those with BMI <30 kg/m2 suggesting that higher BMI alone should not preclude use of LA-CAB/RPV in eligible individuals.
Authors
- Emily Huesgen
- Amanda Binkley (ORCID: https://orcid.org/0000-0002-0273-0176)
- Karam Mounzer (ORCID: https://orcid.org/0000-0001-8537-7103)
- Eric Farmer
- Emily Hiserodt
- Marisa Brizzi (ORCID: https://orcid.org/0000-0002-6986-2042)
- Christina Maguire (ORCID: https://orcid.org/0000-0002-5590-2736)
- William R. Short (ORCID: https://orcid.org/0000-0003-4225-8336)
- Peter Sung
- Amy L. Graziani
- Helen C. Koenig
- Jillian Baron (ORCID: https://orcid.org/0000-0001-5702-5848)
- Antoneta Karaj
- Pallavi Chary
- Kaitlyn Rueve
Institutions
- Indiana University Health (US)
- Penn Presbyterian Medical Center (US)
- Hospital of the University of Pennsylvania (US)
- Presbyterian Medical Center (KR)
- Indiana University – Purdue University Indianapolis (US)
- University of Cincinnati (US)
- University of Pennsylvania (US)
- Philadelphia Fight (US)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1093/cid/ciae579
- Citations
- 10
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.89